CSL Announces Licence to Market and Distribute Dermatology Range from Intendis GmbH

CSL Announces Licence to Market and Distribute Dermatology Range from Intendis GmbH

Melbourne, Australia — 26/06/2006

German-based company, Intendis GmbH (a subsidiary of Schering AG) has granted CSL Limited an exclusive license to market and distribute three of their better known products in Australia.

The products include AdvantanTM, a topical corticosteroid for the treatment of eczema; FinaceaTM, for the treatment of rosacea and acne; and ScheriproctTM, used in the treatment of haemorrhoids.

‘This new arrangement offers an excellent fit with CSL’s existing in-licensed product range’, CSL’s Sales and Marketing Director Dr John Anderson said today.

‘It allows CSL to offer more comprehensive support to Australian dermatologists and general practitioners across a wider variety of disease states’ Dr Anderson said.

All products are currently marketed in Australia and will be further supported through sales and marketing efforts alongside other CSL products in the dermatology portfolio.

Download this release: PDF icon CSL Announces Licence to Market and Distribute Dermatology Range from Intendis GmbH

For further information please contact:
Dr Rachel David
Director, Public Affairs CSL Ltd
Ph 0401 775 779.
© 2016 CSL Limited